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Abstract 1 
The pharmacokinetic (PK) profile of tulathromycin, administered to calves 2 
subcutaneously at the dose rate of 2.5 mg/kg, was established in serum, inflamed 3 
(exudate) and non-inflamed (transudate) fluids in a tissue cage model. The PK profile 4 
of tulathromycin was also established in pneumonic calves. For Mannheimia 5 
haemolytica and Pasteurella multocida, tulathromycin Minimum Inhibitory 6 
Concentrations (MIC) were approximately 50 times lower in calf serum than in 7 
Mueller Hinton Broth. The breakpoint value of the PK/pharmacodynamic (PD) index 8 
(AUC(0-24h)/MIC) to achieve a bactericidal effect was estimated from in vitro time-kill 9 
studies to be approximately 24 h for M. haemolytica and P. multocida.  A population 10 
model was developed from healthy and pneumonic calves and, using Monte Carlo 11 
simulations, PK/PD cut-offs required for the development of Antimicrobial 12 
Susceptibility Testing (AST) were determined. The population distributions of 13 
tulathromycin doses were established by Monte Carlo Computation (MCC). The 14 
computation predicted a Target Attainment Rate (TAR) for a tulathromycin dose rate 15 
of 2.5 mg/kg of 66% for M. haemolytica and 87% for P. multocida. The findings 16 
indicate that free tulathromycin concentrations in serum suffice to explain the efficacy 17 
of single dose tulathromycin in clinical use, and that a dosage regimen can be 18 
computed for tulathromycin using classical PK/PD concepts. 19 
 20 
Introduction 21 
Good clinical efficacy and bacteriological cure with macrolides in human and animal 22 
medicine are commonly achievable with plasma/serum concentrations that are lower, 23 
even much lower, than the in vitro MICs for major lung pathogens. This is the case 24 
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for tulathromycin (Nowakowski, Inskeep et al., 2004), gamithromycin (Huang, 25 
Letendre et al., 2010) and tildipirosin (Menge, Rose et al., 2012), three agents of the 26 
triamilide sub-class, licensed for farm animal use. Because of the disparity between 27 
in vivo plasma concentration and in vitro MICs, the application of classical PK/PD 28 
concepts to macrolides has frequently been challenged. This has led some authors 29 
and regulatory authorities to claim that there is no plasma concentration-effect 30 
relationship for macrolides. A corollary has been to propose that dosages for clinical 31 
use can only be established in a clinical setting using a dose-titration approach. 32 
However, an alternative to this view is to question the value and applicability of the in 33 
vitro MIC data obtained in matrices optimized for bacterial growth, as for example in 34 
Mueller Hinton Broth (MHB). This issue is addressed in this article.  35 
To explain the clinical efficacy of macrolides at recommended dose rates, 36 
alternatives to the PK/PD paradigm have been proposed. For example, many authors 37 
have proposed that lung tissue concentration is more relevant than that in 38 
plasma/serum, in determining outcome of treatment with macrolides. For 39 
tulathromycin, the drug investigated in the present paper, lung homogenate 40 
concentrations in pigs and calves were more than 50-fold higher than corresponding 41 
plasma concentrations (Nowakowski, Inskeep et al., 2004; Villarino, Lesman et al., 42 
2013). However, it is now widely accepted that lung homogenate is not the biophase 43 
for lung infections (Mouton, Theuretzbacher et al., 2008; Villarino, Brown et al., 2013; 44 
Villarino, Lesman et al., 2013; Villarino, Lesman et al., 2013; Villarino, Brown et al., 45 
2014). The two pathogens considered in this article, Pasteurella multocida and 46 
Mannheimia haemolytica, are strictly extracellular pathogens and pulmonary 47 
epithelial lining fluid (PELF) is the main location for such extracellular organisms. In 48 
some studies, PELF concentrations have exceeded the plasma non-protein bound 49 
Page 3 of 39
Journal of Veterinary Pharmacology and Therapeutics
Journal of Veterinary Pharmacology and Therapeutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 
 
concentrations, leading to a view of the lung as a local drug “reservoir”, able to 50 
control the local extracellular concentration. However, in vivo conditions are dynamic 51 
and any (very slow) release of drug from the lung (very long half-life) would be 52 
unable to maintain an effective local extracellular concentration. Consequently, the 53 
lungs should, rather, be viewed not as a “reservoir” but as a “sump”. According to 54 
Kiem and Schentag (Kiem & Schentag, 2008), it is the lysis of cells (containing high 55 
drug concentrations) during the bronchoalveolar lavage procedure required to collect 56 
PELF that explains high PELF drug concentrations. Therefore, these authors, 57 
consider the high drug concentrations in PELF to be artefactual. 58 
Many reports have shown that macrolides may accumulate in high concentrations in 59 
neutrophils and macrophages (Scorneaux & Shryock, 1998; Scorneaux & Shryock, 60 
1999; Villarino, Brown et al., 2013). Uptake by and subsequent off-loading of drug, 61 
for example azithromycin, from these cells in vivo has been proposed as a 62 
mechanism of drug delivery to the biophase (Gladue, Bright et al., 1989; Mandell & 63 
Coleman, 2001; Bosnar, Kelneric et al., 2005). However, in vivo evidence to support 64 
this hypothesis is entirely lacking and it may also be questioned on theoretical 65 
grounds using mass balance considerations. Even assuming that the entire 66 
circulating neutrophil pool is in the lung extracellular water (about 2x1011 cells 67 
corresponding to a volume of 6mL for a 50kg calf) and also that the total macrolide 68 
content is immediately released, the neutrophil pool would be unable to dynamically 69 
control the local biophase concentration over the several days of the claimed 70 
duration of drug efficacy. We conclude that it is most improbable that these cells can 71 
be accorded the role of “truck-containing bullets off-loading their drug content” and 72 
targeting the biophase, thereby achieving in vivo high local and sustained drug 73 
concentrations (Toutain, 2009). This opinion is consistent with the fact that, using 74 
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microdialysis techniques, it has been shown that inflammation generally does not 75 
increase local antimicrobial drug (AMD) concentrations (Muller, dela Pena et al., 76 
2004).  77 
In light of the challenges to the applicability of the PK/PD paradigm to macrolides, the 78 
aim of this study was to generate PK and PD data for tulathromycin for M. 79 
haemolytica and P. multocida in calves to show that it is possible to establish 80 
therapeutically relevant in vivo PK/PD relationships for a macrolide, as for any AMD 81 
(Toutain, del Castillo et al., 2002; Toutain & Lees, 2004). More specifically, using a 82 
population PK model of tulathromycin disposition, we have estimated PK/PD cut-offs 83 
of tulathromycin to compare their Target Attainment Rate (TAR) with the current 84 
clinical breakpoints (BP) used for Antimicrobial Susceptibility Testing (AST) in cattle. 85 
Finally, using MIC distributions of M. haemolytica and P. multocida, we have 86 
generated by Monte Carlo computation (MCC) the population distribution of the 87 
tulathromycin doses to determine the corresponding TAR for the currently marketed 88 
dose of 2.5 mg/kg. This has provided a comparison of results obtained using a 89 
PK/PD approach with the dose derived from the dose titration approach. 90 
 91 
Materials and Methods 92 
Animals and procedures 93 
This study was carried out in strict accordance with the recommendations in the 94 
Guide for the Care and Use of Laboratory Animals of the National Institutes of 95 
Health. The protocol was approved by the Ethics and Welfare Committee of the 96 
Royal Veterinary College and the UK Home Office (Project License 70/6986) and all 97 
efforts were made to minimize suffering. 98 
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 99 
A PK study was conducted in 10 healthy female Aberdeen Angus calves and 16 100 
calves that were subjected to an experimental pulmonary infection. For healthy 101 
calves, body weights were in the range 145-204 kg and ages ranged from 79-131 102 
days.  Tissue cages were implanted subcutaneously in the paralumbar fossa, under 103 
general anesthesia, as described by Sidhu et al. (Sidhu, Shojaee Aliabadi et al., 104 
2003). Tulathromycin (Draxxin®, Pfizer Animal Health, Sandwich, Kent, UK) was 105 
injected subcutaneously into the flank at a dose rate of 2.5 mg/kg at zero time. Also 106 
at zero time, 0.5 mL of 1% w/v sterile lambda carrageenan solution in saline 107 
(Viscarin, Marine Colloids, Springfield, Ill, U.S.A.) was injected into a single tissue 108 
cage. This cage was used to harvest exudate. A second, unstimulated cage was 109 
used to collect non-inflammatory fluid (transudate).  110 
A pneumonia model using M.haemolytica type A1; ref M 7/2 was used in 16 two-111 
week old Holstein Friesian bull calves. Upon arrival, animals were treated with a 112 
single subcutaneous dose of florfenicol 40 mg/kg bodyweight (Nuflor, Schering-113 
Plough Animal Health, Middlesex, UK), to ensure freedom from sub-clinical 114 
infections. Animals were weaned at 5-6 weeks of age, after which they were group 115 
housed until the start of the study. The calves were 12-13 weeks of age at the 116 
commencement of the study. A M. haemolytica inoculum containing 1.27-9.60 109 117 
cfu/mL was used to induce pneumonia as previously described (Sarasola, Jernigan 118 
et al., 2002). 119 
 120 
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Sampling procedures 121 
For healthy calves, blood samples (10 mL volume) were collected, protected from 122 
light, from a jugular vein, into vacutainers (Becton, Dickinson and Company, Oxford, 123 
Oxon, U.K.) without anticoagulant, before and regularly up to 336 h after injection of 124 
tulathromycin. Exudate and transudate samples (1.5 mL volume) were collected, 125 
protected from light, before and regularly up to 336 h after dosing. All samples were 126 
centrifuged (2000 g for 10 min at 4°C) and supernatants stored at -70°C prior to 127 
assay for tulathromycin concentration and for measurement of ex vivo antibacterial 128 
activity. For experimentally infected calves, blood samples were collected regularly 129 
from time 0 to 48 h after injection of tulathromycin and samples were processed as 130 
described for the healthy calves. 131 
 132 
Analysis of tulathromycin in serum, exudate and transudate 133 
Serum, exudate and transudate samples were assayed for tulathromycin, using a 134 
tandem mass spectrometry method, adapted from Scheuch et al. (Scheuch, Spieker 135 
et al., 2007). 136 
The methods were validated according to the published guideline (Committee for 137 
medicinal products for human use (CHMP), 2011). Selectivity was checked for each 138 
matrix. A quadratic model weighted by 1/X2 was selected over the calibration range 139 
5-1000 ng/mL. Intra-day and inter-day precisions were less than 15% and the 140 
accuracy ranged from 102 to 106%. The lower limit of quantification (LLOQ) was 5 141 
ng/mL with a precision of 8% and an accuracy of 105%. The processed extracts of 142 
tulathromycin were stable in the autosampler at room temperature for at least 24 h.  143 
 144 
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Pharmacokinetic-pharmacodynamic modelling of in vitro time-kill data 145 
PK/PD modelling of in vitro time-kill data was undertaken to compute the BP value of 146 
the PK/PD index (AUC(0-24h)/MIC) selected to express tulathromycin in vivo activity 147 
i.e. its bacteriostatic, bactericidal or 4 log10 decrease in count potency. Data from 148 
previously reported time-kill studies, using both MHB and calf serum as matrices, 149 
were used for PK/PD modelling (see for details (Lees, Illambas et al., 2016)). Briefly, 150 
six isolates each of the species M. haemolytica and P. multocida were investigated, 151 
using  tulathromycin concentrations corresponding to 0.25, 0.5, 1, 2 and 4 x multiples 152 
of MIC. The bacterial growth, after 24 h incubation in the absence or presence of a 153 
given tulathromycin concentration (expressed as log10 cfu/mL subtracted from the 154 
initial inoculum count log10 cfu/mL), was measured as the response to the 155 
tulathromycin in vitro activity (dependent variable); the ratios of  AUC(0-24h)/MIC were 156 
calculated for each isolate at each of the five tulathromycin concentrations tested and 157 
these comprised the independent variable for fitting data to a sigmoidal Emax model to 158 
estimate parameters of tulathromycin efficacy and potency (Equation 1).  159 
 max
0
50
N
N N
E C
E E
EC C
×
= +
+
  (1) 160 
where E  is the bacterial growth for a given concentration of tulathromycin; 
0E  is the 161 
corresponding bacterial growth in the absence of drug (control samples); 
maxE  (the 162 
efficacy parameter) is the maximum antimicrobial growth inhibition determined as the 163 
change in log10 cfu/mL over 24 h incubation; 50
NEC  (the potency parameter) is the 164 
AUC(0-24h)/MIC value providing 50% of the maximum antibacterial effect; C (the 165 
independent variable) is the concentration term (expressed as AUC(0-24h)/MIC); and N 166 
is the Hill coefficient. The AUC(0-24h)/MIC corresponding to a bacteriostatic effect 167 
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(E=0, no change form initial inoculum count), a bactericidal effect (E=-3, a 3log10 168 
reduction from initial inoculum count) or (E=-4 a 4log10 reduction from initial inoculum 169 
count) were computed by solving equation 1 for each isolate of each organism in 170 
MHB and serum (Aliabadi & Lees, 2001; Lees, Shojaee Aliabadi et al., 2004). 171 
 172 
Pharmacokinetic analyses 173 
Tulathromycin concentration-time data in serum, exudate and transudate in individual 174 
calves were analyzed using the WIN-NONLIN regression program (Pharsight 175 
Corporation, Mountain View, CA, USA) submitted to non-compartmental analysis 176 
using the statistical moment approach. 177 
A more advanced population analysis was carried out with Phoenix (Phoenix 178 
WinNonlin 6.3 and NLME1.2; Certa a, L.P., St. Louis, MO, USA) to analyze 179 
simultaneously the serum concentrations obtained from the 10 control calves and the 180 
16 calves subjected to an experimental infection. The more specific goal of the 181 
population analysis was to develop a basic model of tulathromycin disposition in 182 
calves, in order to compute the PK/PD cut-off values that could be used 183 
subsequently to select a clinical BP for an AST that will be adapted to the calf. As the 184 
BP for any AST is always a single value (for a given species and a given pathogen) a 185 
PK model including different co-variates was not required for this objective. 186 
Nevertheless, we explored the health status (pneumonic vs. control calves) as a 187 
relevant co-variate to assess the influence, if any, of an experimentally induced 188 
pneumonia on tulathromycin disposition in the calf. 189 
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The selected structural model was a bi-exponential model for an extravascular route 190 
of administration. The parameterisation was carried out in terms of macroconstants 191 
corresponding to equation 2: 192 
( ) ( ) ( ) ( ) ( )Y t A EXP t B EXP t A B EXP KA tα β= × − × + × − × − + × − ×   (2) 193 
Where A and B (ng/mL) are intercepts and Ka, Alpha and Beta are slopes (1/h) with 194 
Ka>alpha>beta. The estimated fixed parameters (the thetas vector) are reported as 195 
their typical values (tv). The second component of a mixed effect model is the 196 
random component (random effect). The Between Subject Variability (BSV) was 197 
modeled using an exponential model of the form: 198 
 ( )1i iEXPθ θ η= ×   (3) 199 
where 
iθ  is the value of theta in the i
th animal, 
1θ  is the typical population value of 200 
this theta and 
iη , the deviation (noted eta) associated to the  i
th animal from the 201 
corresponding theta  population  value. The distribution of the etas was assumed to 202 
be normal with a mean of 0 and a variance ω2.   203 
 204 
A full covariance matrix of the etas was estimated. From the diagonal of this matrix, 205 
formed by the variance terms in the log-domain, we estimated the BSV using 206 
equation 4 which converts the variance to a coefficient of variation (CV%) in the 207 
original scale.  208 
 ( ) ( )2% 100 1CV EXP ω= × −   (4) 209 
The full matrix of the etas was used for the subsequent Monte Carlo simulations. 210 
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The residual model which reflects unexplained variability after controlling for other 211 
sources of variability (analytical imprecision, departure from the model) was a 212 
multiplicative (proportional) model with ε the error term having a mean of 0 and a 213 
variance σ2. 214 
Parameter estimation with associated standard errors (SE), as a measure of the 215 
precision of the estimation, was based on minimizing an objective function value 216 
using maximum likelihood estimation. A Quasi-Random Parametric Expectation 217 
Maximization (QRPEM) was selected for this estimation. Shrinkage of random effects 218 
towards the means was calculated for the etas and epsilon, allowing use of Empirical 219 
Bayes Estimates -based diagnostic (Karlsson & Savic, 2007). 220 
Monte Carlo simulations with the basic model were performed to generate 1,040 data 221 
sets from 0 to 336 h with a step of 6 h. These simulated serum tulathromycin 222 
concentration profiles were used to determine the PK/PD cut-off values and the 223 
distribution of the apparent clearance, which was used for the population dose 224 
computation. 225 
 226 
Population Dosage prediction 227 
The adequacy of the current dosage of tulathromycin (2.5 mg/kg) was explored by 228 
computing population doses covering different TAR i.e. different percentages of the 229 
population to assess the ability of a PK/PD model to validate or not the current dose 230 
for tulathromycin. For AMDs for which the PK/PD index that best predicts efficacy is 231 
AUC(0-24h)/MIC, the following equation can be used (Equation 5). 232 
 ( )
for 10 days
for 10 days of activity
distributionCl SF MIC
Dose
fu F
× ×
=
×
  (5) 233 
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Where Dose  is the amount of AMD to be administered to guarantee an activity of 234 
tulathromycin over 10 days for a given TAR (see Discussion for the selection of this 235 
10 days duration ); for 10 daysCl  is the population distribution of the apparent plasma 236 
clearance (Cl/F) as obtained in our population PK analysis; SF  is a scaling factor 237 
without units, obtained by dividing the BP value of the PK/PD index  i.e. AUC(0-238 
24h)/MIC, by 24 h, permitting computation of  a SF of 1 for the present analysis; this 239 
indicates that, to achieve a bactericidal action, the average serum concentration of 240 
tulathromycin should be equal to the MIC (see (Toutain, Bousquet-Melou et al., 2007) 241 
for further explanation on derivation of the SF from AUC(0-24h)/MIC); fu  is the free 242 
drug fraction (Anonymous, 2005) (the  binding to serum protein is low, with the bound 243 
fraction ranging from 0.32 to 0.39 in cattle) and we incorporated in equation 5  fu  as 244 
a uniform distribution between 0.61 and 0.68. For the MIC distributions, the results of 245 
a survey kindly provided by J. Watts (Zoetis) giving the MIC distribution of P. 246 
multocida and M. haemolytica from the years 2004 to 2010, obtained in artificial 247 
broth, were used. We first selected all the MICs equal to or less than the BP 248 
proposed by the CLSI i.e. 16 µg/mL; this value is, according to CLSI, the susceptible 249 
pathogen population that clinically can be successfully treated with tulathromycin and 250 
that should therefore be considered to compute a dose. The percentage of 251 
susceptible pathogens was 89.82% and 91.11% for M.haemolytica (n=2233 strains) 252 
and P. multocida (n=2483 strains), respectively. The MHB MICs were then 253 
transformed into  vectors  of equivalent MICs in serum by dividing all reported MICs 254 
by a factor of 50  i.e. by the SF previously determined when comparing MICs in the 255 
two matrices (Lees, Illambas et al., 2016).  256 
 257 
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Dosage distribution was  computed using MCC (n=5000)  in Oracle Crystal Ball 258 
(Oracle Corporation, Redwood Shores, CA, USA) and the range of TAR from 0 to 259 
90% of cases for which a range of dose levels are able to achieve an average serum 260 
concentration equal to the MIC over the 10 days. The dose level corresponding to a 261 
TAR of 90% was considered as the population dose of tulathromycin, given the 262 
actual susceptible MIC distribution and assuming activity duration of 10 days. Finally, 263 
a sensitivity analysis was carried out to apportion the overall variability of the dose 264 
distributions either to the PK variables (clearance, fu) or to the PD variability (MIC). 265 
Figure 1 gives a flowchart of the different steps for data collection and analysis. 266 
Fig.1 267 
 268 
Statistical analyses 269 
PK variables are presented as geometric, harmonic or arithmetic means, as 270 
appropriate, and SEM. Mean differences in AUC(0-24h)/MIC ratios determined in MHB 271 
compared with those determined in serum for bacteriostatic, bactericidal and 4log10 272 
reductions in count were compared by ANOVA. 273 
 274 
Results 275 
Calf in vivo study  276 
Tulathromycin concentrations in serum, exudate and transudate (NCA 277 
analysis) 278 
The mean (+SEM) concentrations of tulathromycin are presented in Fig. 2 (serum, 0-279 
15 h) and Fig. 3 (serum, exudate and transudate, 0-336 h). Maximum concentration 280 
(Cmax) of tulathromycin (0.69 µg/mL) was often observed at the first sampling time (10 281 
min). Concentrations exceeded 0.40 µg/mL up to 12 h and were still quantifiable 282 
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(mean = 0.025 µg/mL) at 336 h. Serum terminal half-life was 84.0 h and mean 283 
residence time (MRT) was 91.4 h (Table 1).  284 
Fig. 2 285 
Fig. 3 286 
 287 
Penetration of tulathromycin into and clearance from carrageenan-induced exudate 288 
and transudate were dissimilar. Concentrations (Cmax) and areas under curves 289 
(AUC(0-last)) were higher in exudate than in transudate; 0.24 and 0.12 µg/mL for Cmax 290 
(P<0.05) and 18.4 and 8.58 µg.h/mL for AUC(0-last) (P<0.05). More importantly , for 291 
both non-vascular fluids concentrations and areas were lower than in serum at all 292 
sampling times, P<0.01 (for serum Cmax = 0.75 µg/mL and AUC(0-last) = 45.1 µg.h/mL) 293 
indicating a lack of tulathromycin accumulation in an inflammatory fluid compared to 294 
serum (see discussion). However, mean values of MRT were similar for all three 295 
fluids, indicating that a state of equilibrium was achieved between the tissue cages 296 
and serum. 297 
 298 
Pharmacokinetic-pharmacodynamic surrogates  299 
PK/PD integration established the surrogates, Cmax/MIC, T>MIC, AUC(0-24h)/MIC and 300 
AUC(0-∞)/MIC for tulathromycin, derived from in vivo concentrations in the PK study 301 
(n=10) and in vitro MICs (n=6 for each species) measured in serum. Based on the 302 
geometric mean serum MICs of 0.04 µg/mL for both P. multocida and M. 303 
haemolytica, Cmax/MIC (18.75±0.11), AUC(0-24h)/MIC (238±5.8h),  AUC(0-∞)/MIC ratios 304 
(1198±6.3h) and T>MIC (281±17.5h) indicated that serum concentrations of 305 
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tulathromycin would be predicted to have a high level of activity against the six 306 
strains each of P. multocida and M. haemolytica investigated. 307 
In vitro PK/PD modelling to establish the breakpoint value of AUC(0-24h)/MIC 308 
The BP value of the PK/PD index was required to compute a dose (SF of equation 309 
5); for both M. haemolytica and P. multocida geometric mean MIC values were 2.07 310 
µg/mL (n = 6 per species) in MHB and 0.04 µg/mL (n = 6) in calf serum (Lees, 311 
Illambas et al., 2016). For both matrices and both organisms, the in vitro time-kill data 312 
provided typical BP estimates of AUC(0-24h)/MIC required to produce, after 24 h 313 
exposure, three levels of growth inhibition (Table 2). A strong bactericidal effect was 314 
observed with a steep concentration-effect relationship. For both M.haemolytica and 315 
P multocida AUC(0-24h)/MIC values providing a 3log10 reduction in count were 316 
approximately 24 h in both serum and MHB. The same result expressed in term of 317 
multiples of MIC was approximately 1 and we selected for the MCS an overall 318 
average BP of 24 h for the PK/PD index (i.e. a SF equal to 1 in equation 5). 319 
The reported AUC/MIC values (in h) are proportionality factors between the 320 
experimental MIC (MICexp) and the average MHB or the average serum 321 
tulathromycin concentration to achieve a bacteriostatic or a bactericidal effect  e.g. 322 
the AUC(0-24h)/MIC of 17.15 h providing  a bacteriostatic effect in  MHB indicates  that 323 
the corresponding average concentration over 24 h in  MHB was 324 
17.15h/24h=0.71times the MIC and that the bactericidal effect in serum was obtained 325 
with a concentration of 38.44h/24h or 1.6 times the MIC. 326 
 327 
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Population analysis 328 
Figure 4 shows the Visual Predictive Check (VPC) i.e. the observed serum 329 
concentration (ng/ml) vs. time (h) and observed and predicted quantiles; this is the 330 
most useful diagnostic plot for the assessment of model adequacy. Typical values of 331 
the primary structural parameters of the model (thetas), the secondary parameters 332 
(AUC and half-life), their associated Standard Error (SE) and the SD of the residual 333 
for the basic model are given in Table 3; for all calves, the tv of the terminal half-life 334 
was 84.8 h (CV 4.8%) and the tv of the population AUC was 46,291 ng*h/mL (CV 335 
11.5%) i.e. very similar values to those computed by the NCA with the 10 control 336 
calves. The estimates of shrinkage were relatively small or moderate and provided 337 
support for the reliability of th  estimates of the random effects. Coefficient of 338 
variation (CV%) of the variance of the etas expressing the BSV are given in Table 4. 339 
They were relatively large for A, alpha and Ka and the inclusion in the model of the 340 
covariate health status largely reduced these CV% (Table 4). 341 
A and B (ng/mL) are intercepts and Ka, Alpha and Beta are slopes (1/h) with 342 
Ka>alpha>beta. CV% was the standard error percentage calculated as 100* SE / 343 
Parameter Value indicating the reliability of the model. Proportional residual error 344 
was 24.5% and the epsilon shrinkage was 0.05375. 345 
Fig.4 346 
 347 
Using the basic structural model, the serum disposition curves (Individual Predicted 348 
values based on individual ETAs) of 1,040 calves were simulated (serum 349 
concentrations predicted from time 0 to 336 h with a step of 6 h). These 1,040 350 
simulations were subjected to a NCA, and partial areas (from 0 to 24h, 0 to 48hWup 351 
to 0 to 240h) were computed; then the corresponding mean serum concentrations 352 
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over these time intervals were calculated. Next, the corresponding quantiles (5 to 353 
95%) were established (Table 5). These serum concentrations can be viewed as the 354 
PK/PD cut-offs for these time intervals and for a selected TAR. For example, if the 355 
claimed duration of tulathromycin activity is 240 h and if a TAR of 90% is expected, 356 
the PK/PD cut-off is 83 ng/mL, indicating that for 90% of the calves it can be 357 
guaranteed that the average serum concentration of tulathromycin will be at least 83 358 
ng/mL over the first 10 days following tulathromycin administration at the nominal 359 
dosage of 2.5mg/kg. As the ratio of MIC obtained in MHB:serum is approximately 360 
50:1, the PK/PD cut-off for a TAR of 90% for an expected duration of activity of 240 h 361 
is 4.15 µg/mL for MHB, a value lower than the current clinical breakpoint of CLSI (16 362 
µg/mL) (Lees, Illambas et al., 2016) but consistent with EMEA opinion (Committee for 363 
medicinal products for veterinary use (CVMP), 2003) (see Discussion). 364 
 365 
Dosage computation 366 
From the MCS, using parameters of the basic model, the corresponding 1,040 367 
apparent serum clearance values were computed (Dose/AUC(0-inf)) with Dose = the 368 
standard tulathromycin dose of 2.5mg/kg. The distribution of these 1,040 serum 369 
clearances (L/kg/day) was right-skewed and this distribution was normalized by a log 370 
transformation (log of the mean clearance of 0.287 and SD of 0.53252). The mean 371 
clearance for the 10 days selected for solving equation 5 was 2.589 in the LN 372 
domain.The distribution of MICs, after  transformation by a scaling factor of 50 to take 373 
into account the serum effect, is presented in Figure 5. 374 
Figures 6 and 7 illustrate the non-cumulative and cumulative distributions of doses 375 
for M. haemolytica and P. multocida, respectively. For a TAR of 90%, the computed 376 
dose for M. haemolytica was 5.3mg/kg, indicating that, with this dose, the average 377 
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serum concentration of tulathromycin over the first 240 h following administration of 378 
this dose will be equal to the MIC of M. haemolytica in 90% of calves. For the 379 
nominal dose of 2.5mg/kg, the corresponding TAR for M. haemolytica was 65.9%. 380 
For a TAR of 90%, the computed dose for P. multocida was 2.52 mg/kg and for the 381 
nominal dose of 2.50 mg/kg, the TAR was 87.2%. 382 
Fig. 5 383 
Fig 6 384 
Fig. 7 385 
To identify the main sources of variability amongst the factors controlling the dose 386 
(plasma clearance, MICs or fu), a sensitivity analysis was performed to apportion 387 
variability to these three factors. The main source of variability for P. multocida was 388 
MIC (76.7%); the BSV of serum clearance was lower (23.0%) and the variability of fu 389 
was negligible. For M. haemolytica, results were very similar with 70.3% of the 390 
variability due to the MIC distribution and 29.2% to the BSV of clearance, indicating 391 
that the data should be relevant for different cattle populations.  392 
 393 
Discussion 394 
The principal findings of the present study are that: (i) contrary to previous claims, the 395 
dosage of tulathromycin can be documented using standard PK/PD concepts;  (ii) the 396 
recommended dose of tulathromycin (2.5mg/kg) is consistent with our calculated 397 
population doses, with computed TARs of 66% and 87% for a 2.50 mg/kg dose for M. 398 
haemolytica and P. multocida, respectively; (iii) tulathromycin did not accumulate in 399 
inflammatory exudate in comparison with serum concentrations; (iv) the BP value of 400 
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the PK/PD index i.e. the AUC(0-24h)/MIC was approximately 24 h, indicating that 401 
tulathromycin has a potent bactericidal effect for a concentration approximately equal 402 
to the MIC; (v) PK/PD cut-offs are consistent with the current BPs of AST issued by 403 
the CLSI and EMA; and (vi) the main source of variability to take into account to 404 
determine a dose for a given animal is of PD origin (MIC) and not the actual 405 
tulathromycin exposure. 406 
 407 
The aim of this study was to determine the adequacy (or not) of the currently 408 
recommended dosage of tulathromycin (2.5mg/kg) for calves, by computing a 409 
population dose covering a range of TARs i.e. the aim was to assess the ability of a 410 
standard PK/PD model to determine a dose for tulathromycin for different 411 
percentages (up to 95%) of the population.  The present PK/PD approach clearly 412 
indicated the therapeutic relevance of serum concentration; and the data further 413 
suggest that other explanations for the efficacy of tulathromycin, including high local 414 
intracellular pulmonary concentration or a specific transportation of the drug by 415 
macrophages or neutrophils to the extracellular biophase in the lung (as discussed in 416 
the Introduction) do not need to be invoked. The dose of tulathromycin was first (prior 417 
to licensing) determined in field studies and was based primarily on clinical efficacy, 418 
because it was considered that the clinical efficacy for this drug could not be derived 419 
from a PK/PD relationship. The present data provide clear evidence that standard 420 
PK/PD concepts would, in fact, have fully sufficed to derive an appropriate dosage for 421 
tulathromycin. The crucial proviso, however, is that, for the PK/PD integration and 422 
modelling approaches to be valid, MICs have to be determined in serum and not, as 423 
is routine and almost universal, in an artificial medium such as MHB. We therefore 424 
conclude that what should be questioned for macrolides is the utilization of in vitro 425 
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MICs in a non-biological fluid such as MHB, when establishing PK/PD relationships 426 
as a basis for dosage determination.  427 
The main limitation to our computations is the selected value of the SF used to 428 
transform MICs derived from the epidemiological survey and obtained in broth, into 429 
equivalent MICs in serum. A factor of 50 was used, based on broth:serum MIC ratios 430 
for tulathromycin reported in our previous paper (Lees, Illambas et al., 2016). This 431 
revealed a very large serum effect on the potency of tulathromycin, as had been 432 
previously reported by others (Godinho, Keane et al., 2005). For example, Godhino 433 
et al (Godinho, 2008) obtained a lower broth:serum MIC ratio (up to 16) but in the 434 
presence of only 40% bovine serum (rather than the 100% serum used in the present 435 
study). 436 
As the ratio MHB:serum MIC is approximately 50, the PK/PD cut-off (in MHB) for a 437 
TAR of 90% for  an expected duration of activity of  240 h is 4.15 µg/mL, a value 438 
almost four times  lower than the current clinical BP of the CLSI (16 µg/mL) but more 439 
consistent with the EMA/CVMP BP of ≤ 8 µg/mL (Committee for medicinal products for 440 
veterinary use (CVMP), 2003) supporting the validity of our PK/PD approach. 441 
The second possible limitation of our computations is the limited number of animals 442 
that were considered in the population analysis (n=26) with the possibility of having 443 
excluded some relevant variability factors (for example breed of animal). 444 
Nevertheless, we are confident in the overall conclusions, because the sensitivity 445 
analysis showed clearly that the impact of the PK variability is minimal in comparison 446 
with that of PD origin (the epidemiological MICs). Moreover, our population model 447 
included both healthy and diseased animals and it was previously reported that there 448 
were no statistically significant differences in tulathromycin PK between pre-ruminant 449 
calves and adult cattle (Committee for medicinal products for veterinary use (CVMP), 450 
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2003). It is concluded that our PK population model was sufficiently robust for the 451 
purpose of deriving PK/PD cut-offs and population dose distributions. 452 
For single dose administration of a long acting formulation, computation of a dose 453 
using a PK/PD approach requires estimation of the duration of action. To the best of 454 
our knowledge, this duration has not been experimentally determined for cattle. 455 
However, in pigs duration of effectiveness of tulathromycin was determined in a 456 
pulmonary–disease challenge model, using Actinobacillus pleuropneumoniae by 457 
administering a single dose of tulathromycin from 11 to 3 days before the challenge 458 
(Waag, Bradford et al., 2008). These authors concluded that a single dose of 459 
tulathromycin provides up to 9 days of protection against death and severe morbidity. 460 
For the calves used in this study, we define a priori the activity period as that for 461 
which the average serum concentration of tulathromycin was lower than the 462 
EMA/CVMP BP of 8 µg/mL in MHB (equivalent to 160 ng/mL in serum). The MCSs 463 
indicated that the average concentration over the first 10 days following a dose of 2.5 464 
mg/kg was 184 ng/mL and this duration was selected to explore the population dose 465 
distribution, although any other duration could be investigated using this approach. 466 
Computation of a PK/PD dose also requires selection of an appropriate PK/PD index 467 
and determination of its BP value. From the rate and extent of killing of M. 468 
haemolytica and P. multocida by tulathromycin in time-kill studies, the actions were 469 
judged to be, for the former, concentration-dependent in MHB and co-dependent in 470 
serum and, for the latter, co-dependent in both matrices (Lees, Illambas et al., 2016). 471 
Therefore, for both bacterial species, the use of AUC/MIC as a PK/PD surrogate 472 
for/predictor of efficacy is justified (Thomas, Forrest et al., 1998; Schentag, 2000; 473 
Evans, 2005). It should be noted that the time-kill studies were conducted with initial 474 
inoculum counts of the order of 106 to 107 cfu/mL i.e. for an inoculum size likely to be 475 
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relatively high when considering a natural infection; according to Roof (ROOF, 2011) 476 
the total CFU of pathogens in the entire lung for cattle with identified pathogens 477 
ranged from 2x107 – 2x108 CFU for P.multocida and 9x106 – 9x108 CFU for M. 478 
haemolytica, indicating that our time-kill curves were indeed obtained with a  an 479 
appropriate inoculum size, regarding a natural infection. However, for 480 
metaphylaxis/control conditions, for which a lower pathogen load is expected, lower 481 
concentrations of tulathromycin in the biophase are likely to be required, thus 482 
indicating that our results are conservative enough to cover all infectious conditions.    483 
The present findings confirm, in part, previous publications on the PK of 484 
tulathromycin (Nowakowski, Inskeep et al., 2004; Evans, 2005). After subcutaneous 485 
dosing, a terminal half-life of 90 h was reported by these authors, and in this study 486 
half-life was 84 h. However, corresponding AUC(0-last) values were 16.0 µg.h/mL 487 
[1,33] and 45.1 µg.h/mL [this study], where AUC(0-last) was measured over similar 488 
times. The causes of these differences are unknown. Our data further extends the 489 
results of earlier workers, by establishing the distribution of tulathromycin into 490 
extravascular fluids (exudate and transudate) in a tissue cage model. This model 491 
provides a means of sampling inflammatory exudate to allow comparison of the time 492 
course and magnitude of drug penetration into an inflamed (exudate), a non-inflamed 493 
(transudate) fluid and in serum (Higgins, Lees et al., 1984; Sidhu, Shojaee Aliabadi et 494 
al., 2003). Exudate concentrations were always lower than serum concentration, 495 
indicating that there was no specific accumulation of this drug in an inflammatory 496 
biophase, as advocated by those assuming a special delivery of tulathromycin in 497 
inflammatory fluid by accumulation of macrophages or neutrophils.  498 
 499 
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Conclusions 500 
Based on PK/PD modelling, the present study predicts, that the current marketed 501 
dose of tulathromycin is appropriate and that serum concentrations achieved with this 502 
dosage is biologically and clinically relevant.  Recourse to consideration of the high 503 
concentration of tulathromycin in lung homogenate or to a specific transport of the 504 
drug by leucocytes into the biophase is not necessary, and this conclusion 505 
recognizes that the relevant matrix to estimate MIC is serum. 506 
 507 
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Table 1. Pharmacokinetic variables for tulathromycin in serum, exudate and 
transudate in calves  
Variable (units) Serum Exudate Transudate 
Mean SEM Mean SEM Mean SEM 
Cmax (µg/mL) 0.75 0.11 0.24 0.016 0.12 0.016 
Tmax (h)* 2.20 1.18 19.7 2.89 18.0 3.69 
T½ (h)** 84.0 3.61 123.3 10.33 92.1 9.36 
AUC(0-last) (µg.h/mL) 45.1 5.84 18.4 1.99 8.58 0.85 
AUC(0-∞) (µg.h/mL) 47.9 6.31 20.0 2.24 9.50 0.89 
MRT(0-last) (h) 91.4 2.88 87.2 3.54 83.6 6.39 
CI/F (mL/kg/h) 52.1 7.51 - - - - 
Geometric mean unless stated and SEM (n=10) *Arithmetic mean; **Harmonic mean. 
Tmax: Time following dosing at which the maximum concentration (Cmax) occurred. 
T½: Terminal Half-life 
AUC(0-last): Area under the concentration-time graph from 0 to the last sampling time 
AUC(0-∞): Area under the concentration-time graph from 0 to infinity 
MRT: Mean residence time 
CI/F: Clearance scaled by bioavailability 
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Table 2. Results obtained from the killing curve assay.  
Variables Mannheimia haemolytica Pasteurella multocida 
MHB Serum MHB Serum 
Mean SD Mean SD Mean SD Mean SD 
Log Emax (cfu/mL) -4.53 0.66 -5.12 1.43 -5.06 1.41 -4.51 2.03 
Log E0 (cfu/mL) 1.87 0.49 1.97 1.03 1.4 1.04 2.84 1.95 
Log Emax--log E0 
(cfu/mL) 
-6.40 0.58 -7.09 1.97 -6.46 0.97 -7.37 0.75 
Bacteriostatic 
(AUC0-24h/MICexp 
)(h) 
17.15 7.14 19.75 14.72 18.45 11.59 17.28 9.23 
Bactericidal (AUC0-
24h/MICexp) (h) 
21.04 8.39 38.44 30.35 23.7 
(n=5) 
18.03 22.72 
(n=5) 
1.98 
4log10 reduction in 
(AUC0-24h/MICexp) 
(h) 
24.86 
(n=5) 
10.58 32.16 
(n=4) 
11.6 17.19 
(n=4) 
9.45 28.83 
(n=5) 
3.71 
Data (mean, SD, n=6 unless stated) for three levels of growth inhibition of M. 
haemolytica and P. multocida by tulathromycin in Mueller Hinton broth (MHB) and 
serum. 
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Table 3. Population parameters for tulathromycin disposition in calves.   
Parameter Estimate SE CV% 
tvKa 10.7 2.75 25.6 
tvA 389 123 31.7 
tvAlpha 0.2252 0.073 32.4 
tvB 365 39 10.6 
tvBeta 0.008172 0.00040 4.8 
SD of the proportional residual error (eps) 0.245175 0.00683 2.8 
Typical values (tv) of the structural parameters of the population model (thetas), their 
associated Standard Error (SE) and Coefficient of Variation (CV%) and the SD of the 
residual for the model. 
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Table 4. Between Subject Variability (BSV) of tulathromycin disposition in 
calves. 
ETA ηKa ηA ηAlpha ηB ηBeta 
No covariate 129 344 224 53 8 
With the health status as covariate 109 154 122 52 7.8 
Coefficient of variation (CV%) of the variance of the etas (η) indicating the magnitude 
of the BSV for the model without covariate and model with the health status as 
covariate 
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Table 5. PK/PD cut-offs for tulathromycin in calves.  
 Intervals (h) 
Percentiles (%) 0-24 0-48 0-72 0-96 0-120 0-144 0-168 0-192 0-216 0-240 
95 142 132 120 109 99 91 84 78 72 67 
90 172 160 145 132 122 111 103 96 89 83 
80 210 200 183 167 153 140 129 119 111 104 
70 244 229 209 192 176 162 150 139 129 121 
60 278 263 242 222 204 188 174 161 150 140 
50 316 300 277 255 234 217 201 186 172 161 
40 356 337 312 287 264 245 227 210 196 183 
30 408 389 360 331 305 283 262 244 228 214 
20 476 453 419 384 354 329 305 283 263 245 
10 586 555 518 480 445 412 384 359 334 312 
5 685 653 611 566 525 488 454 424 396 370 
These values are the average serum concentrations (ng/mL) of tulathromycin over 10 
incremental time intervals (0-24h, 0-48hW.0-240h) that are at least achieved by a 
given percentage of the calf population (Target Attainment Rate from 5 to 95%) after 
a single subcutaneous administration of tulathromycin at a dose rate of 2.5 mg/kg. 
These values should be multiplied by 50 to give the equivalent PK/PD cut-offs in 
MHB. For example, for 90% TAR and a duration of 0-240 h serum concentration = 
4,150 ng/mL and for 50% TAR and a time interval of 0-120 h serum concentration = 
11,700 ng/mL. 
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Fig.1. Flow chart of the main steps of sample collection, data analysis and 
results outputs for the PK/PD analysis of tulathromycin in calves. 
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Fig. 2. Tulathromycin concentration in serum over the first 12 h after subcutaneous 
administration of tulathromycin in calves. Mean + SEM tulathromycin concentration in 
serum from 0 to 12 h after subcutaneous injection of tulathromycin at a dose rate of 
2.5mg/kg. 
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Fig.3. Tulathromycin concentrations in serum, exudate and transudate over 336 h after 
subcutaneous administration of tulathromycin in calves. Mean + SEM tulathromycin 
concentrations in serum, exudate and transudate for calves after subcutaneous injection of 
tulathromycin at a dose rate of 2.5mg/kg. 
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Fig. 4: Visual Predictive Check: Observed plasma concentration (ng/ml) vs. time (h) 
and observed and predicted quantiles. This diagnostic plot illustrates the observed (red) 5, 
50 and 95%  quantiles superimposed with the predictive check quantiles (black)  5, 50 and 
95% over the observed serum concentrations  (blue symbols).  
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Fig. 5.  MIC distribution of M. haemolytica and P. multocida. Frequency of Minimum 
Inhibitory Concentrations (MICs) for tulathromycin against bovine respiratory pathogens P. 
multocida (n=2483) and M. haemolytica (n=2233). The isolates were from the Zoetis 
surveillance program and were isolated from years 2004 to 2010. MICs (µg/mL) were 
obtained in Mueller Hinton Broth; results are given for only susceptible strains according to 
the CLSI clinical breakpoint (MICs ≤ 16µg/mL) 
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Fig. 6. Population distributions of tulathromycin doses. Comparison of the two 
population distributions of tulathromycin doses, as predicted by a population PK/PD model 
for P. multocida (grey) and M. haemolytica (blue) for duration of action of 240 h. The vertical 
bar indicates the nominal dose of 2.5 mg/kg. Dose (0 to 9000 µg/kg) is indicated on the X 
axis. 
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Fig. 7. Cumulative population distributions of tulathromycin doses. Comparison of the 
two cumulative distributions of doses of tulathromycin, as predicted by a population PK/PD 
model for P. multocida (grey) and M. haemolytica (blue) for a duration of action of 240 h in 
terms of Target Attainment Rate (Y axis: 0-100%). The vertical bar indicates the nominal 
dose of 2.5 mg/kg. Dose (0 to 9000 µg/kg) is indicated on the X axis. 
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